• Most Popular
  • Most Shared

Spectrum Pharma drops after FDA response

NEW YORK
Fri Oct 9, 2009 7:24am EDT

Stocks

   

NEW YORK (Reuters) - Spectrum Pharmaceuticals Inc (SPPI.O) shares tumbled 13 percent to $5.40 in premarket trade on Friday after the company received a complete response letter from the U.S. Food and Drug Administration regarding its supplemental new drug application for its advanced metastatic colorectal cancer treatment Fusilev.

Hot Stocks

The letter stated Fusilev did not demonstrate that the treatment is non-inferior to leucovorin.

(Reporting by Chuck Mikolajczak; editing by Jeffrey Benkoe)
Hot Stocks


More from Reuters

Photo

House approves sweeping healthcare overhaul

WASHINGTON (Reuters) - The House of Representatives gave final approval to a sweeping healthcare overhaul on Sunday, expanding insurance coverage to nearly all Americans and handing President Barack Obama a landmark victory. | Video

» More Top News
A soldier guards hundreds of bags of wheat seed in the isolated district of Nad Ali's district centre in the west of Helmand province, October 17, 2009

Dirty money and Afghan war

As the war in Afghanistan enters its ninth year, the U.S. has finally realized the best way to stop the conflict is to cut the flow of drug money, columnist Bernd Debusmann writes.   Commentary 

    Afghanistan
    Reuters Graphics
    before the bell:

    Pharma takes the spotlight

    Pharmaceutical, healthcare and insurance stocks will grab the spotlight after the House passed a sweeping healthcare overhaul.  Full Article 

    Global Markets